Editas Medicine, Inc.
EDIT· Nasdaq
EDITEditas Medicine, Inc.
Filed Feb 24, 2022 · 10-K · 55 days after period end · 0001558370-22-001950
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $12.47M | $11.42M | $12.28M | $6.12M |
| Net Income | -$41.44M | -$62.50M | -$37.77M | -$25.05M |
| EPS Diluted | — | -$1.00 | — | -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end
